We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays

By LabMedica International staff writers
Posted on 04 Apr 2025

Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the global life sciences and diagnostics company, Revvity Inc. More...

(Waltham, MA, USA). The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits.

The asset purchase relates to the following ELISA kits - CGA-ELISA-NG (Chromogranin A New Gen. ELISA) – CE IVD that aids diagnosis by determining the presence and progression of neuroendocrine tumor, in adults; P3NP-ELISA (N-Terminal Procollagen III Peptide ELISA) – CE IVD that measures the levels of PIIINP in serum, EDTA or Heparin plasma to assess collagen III synthesis and monitor the risk of liver fibrosis in psoriasis patients receiving methotrexate; and CGA-EL-US-NG RUO and P3NP-EL-US RUO which are research use only products for supporting further scientific advancements in research activities.

To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits. IBL has a proven track record of delivering reliable and precise specialty diagnostic tools, including high-quality IVD products. Upon completion of the asset transfer, IBL will assume full responsibility for the manufacturing, distribution and regulatory compliance of the kits. Bringing these products into the Tecan Group will ensure their continued availability to users while upholding the highest quality and regulatory standards.

“This strategic purchase aligns with our commitment to supporting customers with high-quality solutions while strengthening our portfolio in specialty diagnostics," said Mukta Acharya, Head of Tecan’s Life Sciences Business. "As regulatory requirements continue to evolve, we are proactively expanding our offering to ensure laboratories have access to reliable, compliant solutions that meet their needs today and in the future. Tecan and Cisbio have a long-standing collaboration in the IVD sector. The transition of these important ELISA kits marks a strategic step to expand the IBL specialty diagnostics portfolio under IVDR.”


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Mini Vortex Mixer
Vornado
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: PhD researcher Olivia Moscatelli and Associate Professor Jason Tye-Din with the highly sensitive technology used to detect the critical IL-2 signal (Photo courtesy of WEHI)

Groundbreaking Blood Test Detects Celiac Disease in Patients Without Gluten Exposure

Getting a reliable diagnosis for coeliac disease has long required patients to endure weeks of consuming gluten—a painful process for many already following gluten-free diets. Now, a groundbreaking blood... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.